Maxcyte (MXCT) Total Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has 7 years of Total Current Liabilities data on file, last reported at $10.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.2 million, down 19.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.2 million (down 19.8% YoY), and the FY2025 annual result was $14.3 million, down 9.56% from the prior year.
• Total Current Liabilities fell to $10.2 million in Q1 2026 per MXCT's latest filing, from $14.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $18.1 million in Q2 2022 and troughed at $10.2 million in Q1 2026.
• A 5-year average of $15.0 million and a median of $15.5 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 44.46% in 2022, then fell 27.08% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $15.4 million in 2022, then rose by 15.74% to $17.9 million in 2023, then declined by 11.65% to $15.8 million in 2024, then fell by 9.56% to $14.3 million in 2025, then declined by 28.42% to $10.2 million in 2026.
• Business Quant data shows MXCT's Total Current Liabilities at $10.2 million in Q1 2026, $14.3 million in Q4 2025, and $16.1 million in Q3 2025.